Ryvu: Funding, Investors & Team (Sep 2026)
Ryvu is a biopharmaceutical company that is creating small-molecule treatments to overcome the challenges of current oncology therapies.
Ryvu has raised $45.1M across 3 funding rounds on record, the most recent an undisclosed round of $8.7M announced in Mar 2024.
That round is in line with the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ryvu Company Profile and Key Stats
Latest funding round on record: Mar 2024.
Ryvu Funding Rounds
Ryvu raised $22.4M in an undisclosed round announced in Aug 2022.
1.1 years later, an undisclosed round of $14.0M was announced in Sep 2023.
6 months later, an undisclosed round of $8.7M was announced in Mar 2024.
Ryvu Founders and Leadership Team
Contact details for the Ryvu team: 1 of 1 has an email address on file.
Start 14-day free trial →Ryvu Funding Compared to Other Biotechnology Startups
Ryvu's latest round of $8.7M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ryvu in Biotechnology and Krakow
Companies Similar to Ryvu
We're on a mission to revolutionize the use of insects, maximizing their potential in various industries. Our…
Quantum was created to develop solutions that address specific difficulties in cardiac surgery, cardiology,…
BioCam designs and manufactures an endoscopic capsule for imaging of the digestive system along with…
Orthoget is a progressive company specializing in bioengineering that has been engaged in research and…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
Computomics applies AI to bioinformatics data to enable rapid understanding of genomics and drive advanced…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Ryvu Funding FAQs
What does Ryvu do?
Ryvu is a biopharmaceutical company that is creating small-molecule treatments to overcome the challenges of current oncology therapies.
How much funding has Ryvu raised?
Ryvu has raised $45.1M across 3 rounds on record. The most recent is an undisclosed round of $8.7M announced in Mar 2024.
When did Ryvu last raise funding?
Ryvu's most recent funding round on record is an undisclosed round of $8.7M, announced in Mar 2024.
Who is the CEO of Ryvu?
Pawel Przewiezlikowski is listed as CEO at Ryvu.
Where is Ryvu headquartered?
Ryvu is based in Krakow, Malopolskie, Poland.
How many employees does Ryvu have?
Ryvu is in the 251-500 employee band.
How does Ryvu's funding compare to other Biotechnology startups?
Ryvu's latest round of $8.7M is in line with the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Ryvu Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ryvu is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.